Join us for a special community event co-hosted by Cicada HTH and QUT BridgeTech, bringing together medtech entrepreneurs, researchers, and industry experts for a day of learning, networking, and community building.

This month’s theme, AI and Personalisation in Medtech, explores how artificial intelligence is reshaping the future of healthcare—unlocking new opportunities for personalised treatments, advanced diagnostics, and smarter medical devices.

Whether you’re a founder, mentor, researcher, or part of the broader medtech ecosystem, this event is designed to connect you with peers, spark new ideas, and strengthen ties across the NSW medtech community.

Speakers

Hear from industry leaders, founders, and commercialisation experts, including:

Philip Crealy – Senior Manager, Commercialisation, University of Newcastle
Darpan Shidid – Manager, Strategic Projects, Sydney Biomedical Accelerator
Chris Wilson – CEO, HiFI Ortho
Gordon Malouf – Med-Tech Venture Partner, Cicada Innovations
Lilly Bojarski – General Manager, Cicada HTH

Why Attend

Explore how AI is transforming medtech innovation.
Connect with entrepreneurs, mentors, and researchers from across NSW.
Learn from real-world medtech success stories and commercialisation journeys.
Discover how Cicada HTH supports startups and innovators at every stage.

Who Should Attend

Medtech entrepreneurs and startups
Researchers and EMCRs
Industry mentors and program participants
Commercialisation teams and ecosystem partners

Capacity is limited. Register now to secure your place at this important gathering of the healthtech and biotech innovation community.

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.